Figures & data
Notes: A fixed-effects model was used. The square with the corresponding horizontal line represents the OR and 95% CI of each study. The area of the square reflects the weight of the study. The diamond represents the pooled OR and 95% CI. The “case” represents patients with severe radiation-induced side effects and “control” represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a2, mucositis; a3, gastrointestinal and genitourinary toxicity; a3-1, gastrointestinal reactions (nausea and vomiting); a3-2, gastrointestinal reactions (diarrhea, rectal pain, obstipation, bleeding and proctitis); a4, dysphagia; a5, salivary gland; b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis, skin telangiectasia and breast appearance); b1-1, subcutaneous fibrosis; b2, gastrointestinal and genitourinary toxicity; b2-1, gastrointestinal toxicity; b2-2, genitourinary toxicity; b2-3, erectile dysfunction; b3, radiation pneumonitis; b4, mucous membrane; b5, salivary gland.
Abbreviations: M–H, Mantel–Haenszel; OR, odds ratio.
Abbreviations: M–H, Mantel–Haenszel; OR, odds ratio.
Notes: The “case” represents patients with severe radiation-induced side effects and “control” represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a2, mucositis; a3, gastrointestinal and genitourinary toxicity; a3-1, gastrointestinal reactions (nausea and vomiting); a3-2, gastrointestinal reactions (diarrhea, rectal pain, obstipation, bleeding and proctitis); a4, dysphagia; a5, salivary gland.
Abbreviation: M–H, Mantel–Haenszel.
Abbreviation: M–H, Mantel–Haenszel.
Notes: The “case” represents patients with severe radiation-induced side effects and “control” represents patients without or with light radiation-induced side effects. b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis, skin telangiectasia and breast appearance); b1-1, subcutaneous fibrosis; b2, gastrointestinal and genitourinary toxicity; b2-1, gastrointestinal toxicity; b2-2, genitourinary toxicity; b2-3, erectile dysfunction; b3, radiation pneumonitis; b4, mucous membrane; b5, salivary gland.
Abbreviation: M–H, Mantel–Haenszel.
Abbreviation: M–H, Mantel–Haenszel.
Notes: The “case” represents patients with severe radiation-induced side effects and “control” represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a2, mucositis; a3, gastrointestinal and genitourinary toxicity; a3-1, gastrointestinal reactions (nausea and vomiting); a3-2, gastrointestinal reactions (diarrhea, rectal pain, obstipation, bleeding and proctitis); a4, dysphagia; a5, salivary gland; b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis, skin telangiectasia and breast appearance); b1-1, subcutaneous fibrosis; b2, gastrointestinal and genitourinary toxicity; b2-1, gastrointestinal toxicity; b2-2, genitourinary toxicity; b2-3, erectile dysfunction; b3, radiation pneumonitis; b4, mucous membrane; b5, salivary gland.
Abbreviation: M–H, Mantel–Haenszel.
Abbreviation: M–H, Mantel–Haenszel.
Notes: The “case” represents patients with severe radiation-induced side effects and “control” represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a3, gastrointestinal and genitourinary toxicity; b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis and skin telangiectasia); b1-1, subcutaneous fibrosis; b2, gastrointestinal and genitourinary toxicity; b2-1, gastrointestinal toxicity; b2-2, genitourinary toxicity; b2-3, erectile dysfunction.
Abbreviation: M–H, Mantel–Haenszel.
Abbreviation: M–H, Mantel–Haenszel.
Notes: The “case” represents patients with severe radiation-induced side effects and “control” represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a3, gastrointestinal and genitourinary toxicity; b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis and skin telangiectasia); b1-1, subcutaneous fibrosis; b2, gastrointestinal and genitourinary toxicity; b2-1, gastrointestinal toxicity; b2-2, genitourinary toxicity; b2-3, erectile dysfunction.
Abbreviation: M–H, Mantel–Haenszel.
Abbreviation: M–H, Mantel–Haenszel.
Notes: The “case” represents patients with severe radiation-induced side effects and “control” represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a2, mucositis; a3, gastrointestinal and genitourinary toxicity; b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis and skin telangiectasia); b1-1, subcutaneous fibrosis; b2, gastrointestinal and genitourinary toxicity; b2-1, gastrointestinal toxicity; b2-2, genitourinary toxicity; b2-3, erectile dysfunction.
Abbreviation: M–H, Mantel–Haenszel.
Abbreviation: M–H, Mantel–Haenszel.
Notes: The “case” represents patients with severe radiation-induced side effects and “control” represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a2, mucositis; a4, dysphagia; b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis and skin telangiectasia).
Abbreviation: M–H, Mantel–Haenszel.
Abbreviation: M–H, Mantel–Haenszel.
Note: Circles represent the actually included studies.
Abbreviations: OR, odds ratio; SE, standard error.
Abbreviations: OR, odds ratio; SE, standard error.